{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:44:27Z","timestamp":1770817467042,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,6,25]],"date-time":"2008-06-25T00:00:00Z","timestamp":1214352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2008,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effects of rivastigmine versus placebo in Parkinson's disease dementia (PDD) patients with elevated or normal\/low plasma homocysteine were determined. In this prospective analysis of a 24\u2010week, randomly assigned, placebo\u2010controlled study of rivastigmine in PDD, subpopulations comprised patients with plasma homocysteine \u226514 \u03bcmol\/L (elevated) or &lt;14 \u03bcmol\/L (normal\/low). Coprimary outcomes were the Alzheimer's Disease Assessment Scale\u2013cognitive subscale (ADAS\u2010cog) and Alzheimer Disease Cooperative Society\u2013Clinical Global Impression of Change (ADCS\u2010CGIC). Secondary outcomes included additional measures of cognition, including attention and executive function, daily function, and neuropsychiatric symptoms. Adverse events (AEs) were monitored. In total, 342 of 541 patients provided samples for analysis, from which 72% had elevated plasma homocysteine. Hyperhomocysteinemic patients showed treatment differences (rivastigmine vs. placebo) of 4.0 on ADAS\u2010cog and 0.7 on ADCS\u2010CGIC (both <jats:italic>P &lt;<\/jats:italic> 0.01), and significant treatment differences on secondary outcomes. Rivastigmine\u2010 and placebo\u2010treated hyperhomocysteinemic patients (16.5% and 14.6%) discontinued the study because of AEs. Patients with normal\/low homocysteine showed no treatment differences on primary or secondary outcomes (1.4 on the ADAS\u2010cog and 0.1 on ADCS\u2010CGIC, both <jats:italic>P =<\/jats:italic> ns); 16.7% and 10.3% rivastigmine\u2010 and placebo\u2010treated patients discontinued because of AEs. Elevated homocysteine was associated with greater rivastigmine treatment differences than normal\/low homocysteine. \u00a9 2008 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21997","type":"journal-article","created":{"date-parts":[[2008,6,25]],"date-time":"2008-06-25T15:02:19Z","timestamp":1214406139000},"page":"1532-1540","source":"Crossref","is-referenced-by-count":26,"title":["Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients"],"prefix":"10.1002","volume":"23","author":[{"given":"Paolo","family":"Barone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanchieh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger M.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"275","article-title":"Biochemistry of homocysteine in health and diseases","volume":"43","author":"Ramakrishnan S","year":"2006","journal-title":"Indian J Biochem Biophys"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011613"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi259"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2005.191"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000246869.49892.77"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051275"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/10284150600583446"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(01)00327-X"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183063.99107.5c"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0462"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705005833"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-006-9114-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.09.006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1035"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.4.563"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_6_18_2","unstructured":"Diagnostic criteria from DSM\u2010IV.American Psychiatric Association;1994."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.10.1747"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21077"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.11.1449"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.10.002"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X110445"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.5.1913"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2000.01595.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01705533"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.1998.15.231"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1995.105"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2006.00967.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2007.01.002"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21997","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:06:55Z","timestamp":1760951215000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,25]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,8,15]]}},"alternative-id":["10.1002\/mds.21997"],"URL":"https:\/\/doi.org\/10.1002\/mds.21997","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,25]]}}}